​

Abivax (ABVX) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

ABVX Stock Forecast

Abivax (ABVX) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $146.11, with a high of $176.00 and a low of $114.00. This represents a 28.19% increase from the last price of $113.98.

- $40 $80 $120 $160 $200 High: $176 Avg: $146.11 Low: $114 Last Closed Price: $113.98

ABVX Stock Rating

Abivax stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

ABVX Price Target Upside V Benchmarks

TypeNameUpside
StockAbivax28.19%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3714
Avg Price Target$142.00$151.29$121.71
Last Closing Price$113.98$113.98$113.98
Upside/Downside24.58%32.73%6.78%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2646---10
Dec, 2546---10
Nov, 2544---8
Oct, 2544---8
Sep, 2543---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 09, 2026Morgan Stanley$145.00$116.9723.96%27.22%
Jan 08, 2026Julian HarrisonBTIG$150.00$126.4818.60%31.60%
Jan 08, 2026Oppenheimer$131.00$126.483.57%14.93%
Dec 18, 2025Yatin SunejaGuggenheim$175.00$117.2449.27%53.54%
Dec 16, 2025Piper Sandler$142.00$110.9827.95%24.58%
Nov 24, 2025Gregory RenzaTruist Financial$140.00$119.1217.53%22.83%
Nov 05, 2025Wolfe Research$176.00$99.6176.69%54.41%
Oct 13, 2025Etzer DaroutBarclays$142.00$93.7751.43%24.58%
Oct 10, 2025Guggenheim$150.00$90.6165.54%31.60%
Oct 06, 2025BTIG$120.00$86.6738.46%5.28%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 09, 2026Morgan StanleyOverweightOverweighthold
Jan 08, 2026CitigroupMarket OutperformMarket Outperformhold
Jan 08, 2026BTIGBuyBuyhold
Dec 18, 2025GuggenheimBuyBuyhold
Dec 16, 2025Piper SandlerOverweightOverweighthold
Dec 16, 2025CitigroupOutperformOutperformhold
Nov 05, 2025Wolfe ResearchOutperforminitialise
Nov 04, 2025CitigroupMarket OutperformMarket Outperformhold
Oct 13, 2025BarclaysOverweightinitialise
Oct 10, 2025GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.47$-3.13$-2.35-----
Avg Forecast$-2.83$-2.55$-1.98$-2.73$-2.63$-2.32$-1.53$-0.52
High Forecast$-1.53$-0.86$-1.79$-2.57$-2.34$-0.79$-0.52$-0.18
Low Forecast$-4.43$-4.15$-2.15$-2.92$-2.98$-3.78$-2.50$-0.85
Surprise %-12.72%22.75%18.69%-----

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$37.00K-------
Avg Forecast$649.45K$1.65M$431.20K$7.27M$5.53M$3.83M$134.18M$283.42M
High Forecast$933.47K$2.44M$447.40K$9.31M$8.20M$5.68M$199.08M$420.53M
Low Forecast$420.50K$809.12K$414.09K$6.21M$2.72M$1.88M$65.96M$139.34M
Surprise %-94.30%-------

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-41.36M$-69.85M$-147.40M-----
Avg Forecast$-121.73M$-109.67M$-85.06M$-117.57M$-113.10M$-100.04M$-66.03M$-22.59M
High Forecast$-65.94M$-37.19M$-77.30M$-110.73M$-100.84M$-33.92M$-22.39M$-7.66M
Low Forecast$-190.93M$-178.65M$-92.47M$-125.63M$-128.52M$-162.95M$-107.56M$-36.80M
Surprise %-66.03%-36.32%73.29%-----

ABVX Forecast FAQ

Is Abivax stock a buy?

Abivax stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Abivax is a favorable investment for most analysts.

What is Abivax's price target?

Abivax's price target, set by 8 Wall Street analysts, averages $146.11 over the next 12 months. The price target range spans from $114 at the low end to $176 at the high end, suggesting a potential 28.19% change from the previous closing price of $113.98.

How does Abivax stock forecast compare to its benchmarks?

Abivax's stock forecast shows a 28.19% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Abivax over the past three months?

  • January 2026: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Abivax’s EPS forecast?

Abivax's average annual EPS forecast for its fiscal year ending in December 2024 is $-2.73, marking a 16.17% increase from the reported $-2.35 in 2023. Estimates for the following years are $-2.63 in 2025, $-2.32 in 2026, $-1.53 in 2027, and $-0.52 in 2028.

What is Abivax’s revenue forecast?

Abivax's average annual revenue forecast for its fiscal year ending in December 2024 is $7.27M, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $5.53M, followed by $3.83M for 2026, $134.18M for 2027, and $283.42M for 2028.

What is Abivax’s net income forecast?

Abivax's net income forecast for the fiscal year ending in December 2024 stands at $-118M, representing a -20.23% decrease from the reported $-147M in 2023. Projections indicate $-113M in 2025, $-100M in 2026, $-66.034M in 2027, and $-22.591M in 2028.